Cochrane · systematic review · CD009145
Bezafibrate for primary biliary cirrhosis
Rudic, JS, Poropat, G, Krstic, MN, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 8 · 72.7%Low 2 · 18.2%Moderate 1 · 9.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bezafibrate compared with no intervention for primary biliary cirrhosis
Population: patients with primary biliary cirrhosis.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Bezafibrate vs no intervention | RD 0 | 3 studies · 60 participants | Very low Downgraded: risk of bias, imprecision |
Liver morbidity Bezafibrate vs no intervention | RD 0 | 3 studies · 60 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Bezafibrate vs no intervention | RR 5.4 [0.69, 42.32] | 3 studies · 60 participants | Very low Downgraded: risk of bias, imprecision |
Serum alkaline phosphatases (U/L) Bezafibrate vs no intervention | no estimate extracted | 4 studies · 79 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Serum alkaline phosphatases (U/L) ‐ duration of administration 6 months Bezafibrate vs no intervention | no estimate extracted | 2 studies · 38 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Serum alkaline phosphatases (U/L) ‐ duration of administration 12 to 13 months Bezafibrate vs no intervention | no estimate extracted | 2 studies · 41 participants | Low Downgraded: risk of bias, imprecision |
Serum bilirubin (mg/dl) Bezafibrate vs no intervention | no estimate extracted | 2 studies · 34 participants | Very low Downgraded: risk of bias, imprecision |
Bezafibrate compared with ursodeoxycholic acid for primary biliary cirrhosis
Population: patients with primary biliary cirrhosis.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Bezafibrate vs ursodeoxycholic acid | RD 0 | 2 studies · 69 participants | Very low Downgraded: risk of bias, imprecision |
Liver morbidity Bezafibrate vs ursodeoxycholic acid | RD 0 | 2 studies · 69 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Bezafibrate vs ursodeoxycholic acid | RR 6.19 [0.31, 122.05] | 2 studies · 69 participants | Very low Downgraded: risk of bias, imprecision |
Serum alkaline phosphatases (U/L) Bezafibrate vs ursodeoxycholic acid | no estimate extracted | 2 studies · 48 participants | Moderate Downgraded: risk of bias, imprecision |